Olaparib Improves PFS as Frontline Maintenance in Ovarian Cancer
Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Source: OncLive